Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
In the latest session, Arcus Biosciences Inc (NYSE: RCUS) closed at $21.01 down -1.59% from its previous closing price of $21.35. In other words, the price has decreased by -$1.59 from its previous closing price. On the day, 2.41 million shares were traded. RCUS stock price reached its highest trading level at $21.49 during the session, while it also had its lowest trading level at $20.59.
Ratios:
For a deeper understanding of Arcus Biosciences Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.65 and its Current Ratio is at 3.65. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.22.
On February 26, 2025, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $18 to $24.
On October 21, 2024, H.C. Wainwright started tracking the stock assigning a Neutral rating and target price of $20.H.C. Wainwright initiated its Neutral rating on October 21, 2024, with a $20 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 05 ’26 when Jaen Juan C. sold 31,823 shares for $21.41 per share. The transaction valued at 681,342 led to the insider holds 922,240 shares of the business.
Juan Jaen bought 31,823 shares of RCUS for $692,787 on Jan 05 ’26. On Dec 31 ’25, another insider, Goeltz II Robert C., who serves as the Chief Financial Officer of the company, sold 6,552 shares for $23.38 each. As a result, the insider received 153,186 and left with 67,924 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RCUS now has a Market Capitalization of 2599536640 and an Enterprise Value of 1569523968. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.01 while its Price-to-Book (P/B) ratio in mrq is 5.16. Its current Enterprise Value per Revenue stands at 6.54 whereas that against EBITDA is -4.3.
Stock Price History:
The Beta on a monthly basis for RCUS is 0.84, which has changed by 0.5082556 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, RCUS has reached a high of $26.40, while it has fallen to a 52-week low of $6.50. The 50-Day Moving Average of the stock is -5.99%, while the 200-Day Moving Average is calculated to be 57.62%.
Shares Statistics:
For the past three months, RCUS has traded an average of 1.87M shares per day and 1537160 over the past ten days. A total of 107.10M shares are outstanding, with a floating share count of 81.39M. Insiders hold about 34.24% of the company’s shares, while institutions hold 52.88% stake in the company. Shares short for RCUS as of 1765756800 were 7830605 with a Short Ratio of 4.18, compared to 1763078400 on 9888340. Therefore, it implies a Short% of Shares Outstanding of 7830605 and a Short% of Float of 9.0100005.
